## 1

#### Interpretation: The affirmative debater must defend reducing intellectual property protections for substances that treat diseases. To clarify, they may not defend substances that prevent diseases.

#### Violation: They defend COVID vaccines

#### Medicines treat diseases

Webster (Merriam Webster is America's leading and most-trusted provider of language information, accessed on 6-30-21, Merriam Webster, "Definition of MEDICINE,” https://www.merriam-webster.com/dictionary/medicine)// ww pbj

Definition of medicine 1a: a substance or preparation used in treating disease cough medicine

#### Treatment is different than prevention

Pflanzer 20 (Lydia Ramsey Pflanzer is a healthcare editor for Business Insider. She joined Business Insider in 2015 after graduating from Northwestern University, 4-29-2020, accessed 6/30/21, "Scientists are racing to discover ways to treat and prevent coronavirus. Here's the difference between a treatment and a vaccine.," Business Insider, <https://www.businessinsider.com/whats-the-difference-between-a-vaccine-and-a-treatment-2020-4)//ww> pbj

Vaccines are used to prepare the body's immune system to fight off infections. They work by giving the body a small taste of what the virus is like so that way it can produce antibodies that fight off an intruding virus, ideally keeping people from falling ill. Some vaccines protect better than others, and they're typically administered across broad populations. There are vaccines for some infectious diseases, like the flu, smallpox, measles, and chickenpox. But others, like HIV and hepatitis C, don't have vaccines that protect against them. Vaccines that protect against two other deadly outbreaks, MERS and SARS, have yet to be approved after the outbreaks subsided. There are more than 70 potential coronavirus vaccines in the works, with a number in early human trials. Drugmakers are looking into ways to produce the billions of doses that might be needed to suppress the pandemic. Read more: There are more than 70 potential coronavirus vaccines in the works. Here are the top efforts to watch, including the 16 vaccines set to be tested in people this year. FILE - In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP) FILE - In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP) Associated Press Treatments, on the other hand, are meant to do just that: treat COVID-19, helping patients sickened by the virus survive and recover more quickly. Treatments for disease are there to lessen symptoms and ultimately improve the outcomes of a particular disease. Sometimes, medications can be used preventatively. For instance, patients with high cholesterol might be prescribed a medication called a statin to prevent heart attacks. Some potential coronavirus treatments are being studied to see if they can prevent people from contracting the virus in the first place. For COVID-19, researchers are testing everything from antimalarial medications to antivirals, to even common heartburn medications in hospitalized patients with the hopes that more patients will survive severe forms of the illness and potentially recover faster. Some are looking at ways to use patients' own bodies to fight the virus with antibody treatments.

#### Vaccines specifically are different from medicines

Immunize BC 20 (Immunize British Colombia is a collaborative project of the BC Ministry of Health, the BC Centre for Disease Control (an agency of the BC Provincial Health Services Authority), the regional health authorities (First Nations Health Authority, Fraser Health, Interior Health, Island Health, Northern Health and Vancouver Coastal Health), the BC Pharmacy Association and the Public Health Association of BC. Our mission is to improve the health of British Columbians by continuing to reduce the number of vaccine-preventable diseases, along with the illness, disability and death that they cause, What are vaccines?, Date last reviewed: Thursday, Mar 19, 2020, accessed on 6-30-21, <https://immunizebc.ca/what-are-vaccines)//ww> pbj

Vaccines are products that protect people against many diseases that can be very dangerous and even deadly. Different than most medicines that treat or cure diseases, vaccines prevent you from getting sick with the disease in the first place.

#### Standards:

#### [1] Limits – they explode the topic to include tons of substances that prevent disease rather than treat them like soap, medical supplies, or food and make it so there is *no* unified neg generics. The aff still gets the core of the topic lit: they get medicine, innovation, and global inequality. Explosion of aff ground makes neg prep burden impossible, either killing neg ground or forcing the neg to read generics that barely link, always letting aff win. Force the 1AR to read a definition card with a clear list of what’s included and excluded – otherwise, vote neg since they can’t put a clear limit on the topic.

#### [2] Precision – not defending the text of the resolution justifies the affirmative doing away with random words in the resolution which a] means they’re not within the topic which is a voter for jurisdiction since you can only vote affirmative on the resolution and this debate never should have happened, b] they’re unpredictable and impossible to engage in so we always lose

#### Drop the Debater –

#### [1] sets a precedent that debaters wont be abusive

#### [2] DTA is the same since you drop the aff

#### Voters:

#### [1] Fairness – constitutive to the judge to decide the better debater, only fairness is in your jurisdiction because it skews decision making

#### [2] Education – the only portable education from debate that we care about

#### Competing Interps:

#### [1] reasonability on t is incoherent: you’re either topical or you’re not – it’s impossible to be 77% topical, links to all limits offense

#### [3] judge intervention – judge has to intervene on what’s reasonable, creates a race to the bottom where debaters exploit judge tolerance for questionable argumentation.

#### No RVIs

#### [1] illogical for you to get offense just for being fair – it’s the 1ac’s burden

#### [2] baiting - rvi’s incentivize debaters to read abusive positions to win off theory

## 2

### 1NC – Backlash – Generic

#### Biden PC is key to getting Manchin & Sinema on board – continued negotiations tentatively get their votes – it’s try or die for Tuesday’s vote

Edmondson & Cochrane 10/24 [Catie Edmondson is a reporter in the Washington bureau of The New York Times, covering Congress, Emily Cochrane is a correspondent based in Washington. She has covered Congress since late 2018, focusing on the annual debate over government funding and economic legislation, ranging from emergency pandemic relief to infrastructure, “Biden Meets With Manchin and Schumer as Democrats Race to Finish Social Policy Bill”, 10-24-2021, New York Times, https://www.nytimes.com/2021/10/24/us/politics/biden-manchin-schumer-spending-bill.html]//pranav

WASHINGTON — President Biden huddled with key Democrats on Sunday to iron out crucial spending and tax provisions as they raced to wrap up their expansive social safety net legislation before his appearance at a U.N. climate summit next week. Speaker Nancy Pelosi of California said Democrats were close to completing the bill, displaying confidence that the negotiations over issues like paid leave, tax increases and Medicare benefits that have bedeviled the party for months would soon end. “We have 90 percent of the bill agreed to and written. We just have some of the last decisions to be made,” Ms. Pelosi said on CNN’s “State of the Union,” adding that she hoped to pass an infrastructure bill that had already cleared the Senate and have a deal in hand on the social policy bill by the end of the week. “We’re pretty much there now.” Her comments came as Mr. Biden met with Senators Chuck Schumer of New York, the majority leader, and Joe Manchin III of West Virginia, one of the critical centrist holdouts on the budget bill. The White House called the breakfast at Mr. Biden’s Wilmington home a “productive discussion.” For weeks, intraparty divisions over the scope and size of their marquee domestic policy plan have delayed an agreement on how to trim the initial $3.5 trillion blueprint Democrats passed this year. In order to bypass united Republican opposition and pass the final bill, Democrats are using an arcane budget process known as reconciliation, which shields fiscal legislation from a filibuster but would require every Senate Democrat to unite behind the plan in the evenly divided chamber. The party’s margins in the House are not much more forgiving. Facing opposition over the $3.5 trillion price tag, White House and party leaders are coalescing around a cost of up to $2 trillion over 10 years. They have spent days negotiating primarily with Mr. Manchin and Senator Kyrsten Sinema, Democrat of Arizona and another centrist holdout. House Democratic leaders hope to advance both a compromise reconciliation package and the $1 trillion bipartisan infrastructure package. Liberals have so far balked at voting on the bipartisan deal until the more expansive domestic policy package — which is expected to address climate change, public education and health care — is agreed upon. But Democrats are facing a new sense of urgency to finish the legislation before Mr. Biden’s trip to a major United Nations climate change conference, where he hopes to point to the bill as proof that the United States is serious about leading the effort to fight global warming. “The president looked us in the eye, and he said: ‘I need this before I go and represent the United States in Glasgow. American prestige is on the line,’” Representative Ro Khanna, a California Democrat who met with Mr. Biden last week at the White House, said on “Fox News Sunday.” Democrats are also increasingly eager to deliver the bipartisan legislation to Mr. Biden’s desk before elections for governor in Virginia and New Jersey on Nov. 2, to show voters the party is making good on its promise to deliver sweeping social change. And a number of transportation programs will lapse at the end of the month without congressional action on either a stopgap extension or passage of the infrastructure bill, leading to possible furloughs.

#### Big Pharma hates the plan – empirics – err neg our ev literally cites their press releases

PhRMA ’21 [The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested nearly $1 trillion in the search for new treatments and cures, including an estimated $83 billion in 2019 alone, “PhRMA Statement on WTO TRIPS Intellectual Property Waiver”, 05-05-2021, https://www.phrma.org/coronavirus/phrma-statement-on-wto-trips-intellectual-property-waiver]//pranav

WASHINGTON, D.C. (May 5, 2021) – Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl made the following statement after the United States Trade Representative expressed support for a proposal to waive patent protections for COVID-19 medicines: “In the midst of a deadly pandemic, the Biden Administration has taken an unprecedented step that will undermine our global response to the pandemic and compromise safety. This decision will sow confusion between public and private partners, further weaken already strained supply chains and foster the proliferation of counterfeit vaccines. “This change in longstanding American policy will not save lives. It also flies in the face of President Biden’s stated policy of building up American infrastructure and creating jobs by handing over American innovations to countries looking to undermine our leadership in biomedical discovery. This decision does nothing to address the real challenges to getting more shots in arms, including last-mile distribution and limited availability of raw materials. These are the real challenges we face that this empty promise ignores. “In the past few days alone, we’ve seen more American vaccine exports, increased production targets from manufacturers, new commitments to COVAX and unprecedented aid for India during its devastating COVID-19 surge. Biopharmaceutical manufacturers are fully committed to providing global access to COVID-19 vaccines, and they are collaborating at a scale that was previously unimaginable, including more than 200 manufacturing and other partnerships to date. The biopharmaceutical industry shares the goal to get as many people vaccinated as quickly as possible, and we hope we can all re-focus on that shared objective.”

#### They lash out against infra and use COVID clout to kill it – they have public support, and a win now postpones reform indefinitely which turns case

Fuchs et al. 09/02 [Hailey Fuchsattended Yale University and was an inaugural Bradlee Fellow for The Washington Post, where she reported on national politics**,** Alice Ollstein is a health care reporter for POLITICO Pro, covering the Capitol Hill beat. Prior to joining POLITICO, she covered federal policy and politics for Talking Points Memo, Megan Wilson is a health care and influence reporter at POLITICO, “Drug industry banks on its Covid clout to halt Dems’ push on prices”, 09-02-2021, https://www.politico.com/news/2021/09/02/drug-prices-democrats-lobbying-508127]//pranav

As Democrats prepare a massive overhaul of prescription drug policy, major pharmaceutical companies are mounting a lobbying campaign against it, arguing that the effort could undermine a Covid fight likely to last far longer than originally expected. In meetings with lawmakers, lobbyists for the pharmaceutical industry have issued warnings about the reconciliation package now moving through both chambers of Congress that is set to include language allowing Medicare to negotiate the price of some drugs, which could generate billions of dollars in savings. In those conversations, K Street insiders say, lobbyists have explicitly mentioned that the fight against the coronavirus will almost certainly extend beyond the current surge of the Delta variant. And they’re arguing that now isn’t the time to hit the industry with new regulations or taxes, particularly in light of its successful efforts to swiftly develop vaccines for the virus. “For years, politicians have been saying that the federal government can interfere in the price of medicines and patients won’t suffer any harm,” said Brian Newell, a spokesperson for the Pharmaceutical Research and Manufacturers of America, or PhRMA, in a statement. “But in countries where this already happens, people experience fewer choices and less access to prescription medicines. Patients know if something sounds too good to be true, then it usually is.” The escalating warnings from the pharmaceutical industry are part of what is expected to be one of the more dramatic and expensive lobbying fights in recent memory, and a heightened repeat of the industry’s pushback to actions by former President Donald Trump to target drug prices. The proposal now under consideration in Democrats’ reconciliation package could save the federal government hundreds of billions of dollars by leveraging its ability to purchase prescription drugs, according to a report from the Congressional Budget Office. Without those funds, Democrats won’t be able to pay for the rest of the health care agenda they’ve promised to voters, including expansions of Medicare, Medicaid and Obamacare. But the plan has political power as more than a revenue raiser. Party leaders — from President Joe Biden to Senate Budget Chair Bernie Sanders (I-Vt.) — are touting it as one of the most important components of the $3.5 trillion package, with the potential to lower out-of-pocket health spending for tens if not hundreds of millions of people. Outside advocates have also zeroed in on it as the most consequential policy fight on the horizon. “This is the best chance that we have seen in a couple of decades to enact meaningful reforms to drug pricing policy in the United States that will lower the prices of prescription drugs, and it’s very clear that the drug companies are going all out to stop it,” said David Mitchell, founder of Patients for Affordable Drugs. “This is Armageddon for pharma.” Progressive Democrats and their outside allies believe they’re closer than they’ve been in decades to imposing some price controls, and worry that failure to do so this year will delay progress indefinitely given the possibility of the party losing one or more chambers of Congress in the 2022 midterms. In April, the House passed a fairly aggressive version — H.R. 3 (117) — though a handful of moderate Democrats friendly to the industry have threatened to block it when it comes back to the floor for a vote later this fall. Leadership has largely shrugged off this threat, banking on the fact that the most vulnerable frontline Democrats are vocally in favor of the policy, while most of the dissenters sit in safe blue districts. The Senate is designing its own version, outlined by Sen. Ron Wyden (D-Ore.) in June, as a middle ground between HR3 and the more narrow, bipartisan bill he and Sen. Chuck Grassley (R-Iowa) put forward last Congress. A senior Senate Democratic aide confirmed to POLITICO that the bill is nearly complete and that they’re in the process of shopping it around to undecided senators to make sure it has enough support to move forward in the 50-50 upper chamber. “It makes sense to get buy-in before releasing it rather than releasing it with fingers crossed and then tweaking it once members complain,” the aide said. But the reform push is coming at a time when the pharmaceutical industry is working hand-in-hand with government officials to combat the pandemic and enjoying a boost in public opinion as a result, even as drug costs continue to rise. The companies claim that fundamental changes to their bottom line — in addition to the Medicare provision, the reconciliation bill will likely raise corporate tax rate significantly, as high as 28 percent (a jump of 7 percentage points) — will threaten its current investments in research and development at a historically critical juncture. With the final draft of the bill expected in the coming weeks, the Pharmaceutical Research and Manufacturers of America, the lobbying arm of the pharmaceutical industry, is taking its case public. The group has recently spent at least seven figures on ads pressuring Congress not to change Medicare drug policy.

#### Infra’s k2 stopping existential climate change – warming is incremental and every change in temperature is vital

Higgins 8/16 [Trevor, Senior Director, Domestic Climate and Energy, “Budget Reconciliation Is the Key to Stopping Climate Change”, 08-16-2021, https://www.americanprogress.org/issues/green/news/2021/08/16/502681/budget-reconciliation-key-stopping-climate-change/]//pranav

The United States is suffering acutely from the chaotic changes in climate that scientists now directly attribute to the burning of fossil fuels and other human activity. The drought, fires, extreme heat, and floods that have already killed hundreds this summer across the continent and around the world are a tragedy—and a warning of worsening instability yet to come. However, this week, the Senate initiated an extraordinary legislative response that would set the world on a different path. Enacting the full scope of President Joe Biden’s Build Back Better agenda would put the American economy to work leading a global transition to clean energy and stabilizing the climate. A look at what’s coming next through the budget reconciliation process reveals a ray of hope that is easy to miss amid the fitful negotiations of recent months: At long last, Congress is on the verge of major legislation that would build a more equitable, just, and inclusive clean energy economy. This is our shot to stop climate change. Building a clean energy future must start now Until the global economy stops polluting the air and instead starts to draw down the emissions of years past, the world will continue to heat up, blundering past perilous tipping points that threaten irreversible and catastrophic consequences. Stemming the extent of warming at 1.5 degrees Celsius rather 2 degrees or worse will reduce the risk of crossing such tipping points or otherwise exceeding the adaptive capacity of human society. Every degree matters. Stabilizing global warming at 1.5 degrees Celsius starts with cutting annual greenhouse gas emissions in the United States to half of peak levels by 2030. This isn’t about temporary offsets or incremental gains in efficiency—it’s about the rapid adoption of scalable solutions that will work throughout the world to eliminate global net emissions by 2050 and sustain net-negative emissions thereafter. Building this better future will tackle climate change, deliver on environmental justice, and create good jobs. It will give us a shot to stop the planet from continuously warming. It will alleviate the concentrated burdens of fossil fuel pollution, which are concentrated in systemically disadvantaged, often majority Black and brown communities. It will empower American workers to compete in the global clean energy economy of the 21st century. There is no time to lose in the work of building a clean energy future.

## 3

#### CP: Member nations of the World Trade Organization should enter into a prior and binding consultation with the World Health Organization over reducing intellectual property protections for COVID-19 medicines. Member nations will support the proposal and adopt the results of consultation.

#### WHO says yes – it supports increasing the availability of generics and limiting TRIPS

Hoen 03 [(Ellen T., researcher at the University Medical Centre at the University of Groningen, The Netherlands who has been listed as one of the 50 most influential people in intellectual property by the journal Managing Intellectual Property, PhD from the University of Groningen) “TRIPS, Pharmaceutical Patents and Access to Essential Medicines: Seattle, Doha and Beyond,” Chicago Journal of International Law, 2003] JL

However, subsequent resolutions of the World Health Assembly have strengthened the WHO’s mandate in the trade arena. In 2001, the World Health Assembly adopted two resolutions in particular that had a bearing on the debate over TRIPS [30]. The resolutions addressed:

– the need to strengthen policies to increase the availability of generic drugs;

– and the need to evaluate the impact of TRIPS on access to drugs, local manufacturing capacity, and the development of new drugs

#### Consultation displays strong leadership, authority, and cohesion among member states which are key to WHO legitimacy

Gostin et al 15 [(Lawrence O., Linda D. & Timothy J. O’Neill Professor of Global Health Law at Georgetown University, Faculty Director of the O’Neill Institute for National & Global Health Law, Director of the World Health Organization Collaborating Center on Public Health Law & Human Rights, JD from Duke University) “The Normative Authority of the World Health Organization,” Georgetown University Law Center, 5/2/2015] JL

Members want the WHO to exert leadership, harmonize disparate activities, and set priorities. Yet they resist intrusions into their sovereignty, and want to exert control. In other words, ‘everyone desires coordination, but no one wants to be coordinated.’ States often ardently defend their geostrategic interests. As the Indonesian virus-sharing episode illustrates, the WHO is pulled between power blocs, with North America and Europe (the primary funders) on one side and emerging economies such as Brazil, China, and India on the other. An inherent tension exists between richer ‘net contributor’ states and poorer ‘net recipient’ states, with the former seeking smaller WHO budgets and the latter larger budgets.

Overall, national politics drive self-interest, with states resisting externally imposed obligations for funding and action. Some political leaders express antipathy to, even distrust of, UN institutions, viewing them as bureaucratic and inefficient. In this political environment, it is unsurprising that members fail to act as shareholders. Ebola placed into stark relief the failure of the international community to increase capacities as required by the IHR. Guinea, Liberia and Sierra Leone had some of the world's weakest health systems, with little capacity to either monitor or respond to the Ebola epidemic.20 This caused enormous suffering in West Africa and placed countries throughout the region e and the world e at risk. Member states should recognize that the health of their citizens depends on strengthening others' capacity. The WHO has a central role in creating systems to facilitate and encourage such cooperation.

The WHO cannot succeed unless members act as shareholders, foregoing a measure of sovereignty for the global common good. It is in all states' interests to have a strong global health leader, safeguarding health security, building health systems, and reducing health inequalities. But that will not happen unless members fund the Organization generously, grant it authority and flexibility, and hold it accountable.

#### WHO is critical to disease prevention – it is the only international institution that can disperse information, standardize global public health, and facilitate public-private cooperation

Murtugudde 20 [(Raghu, professor of atmospheric and oceanic science at the University of Maryland, PhD in mechanical engineering from Columbia University) “Why We Need the World Health Organization Now More Than Ever,” Science, 4/19/2020] JL

WHO continues to play an indispensable role during the current COVID-19 outbreak itself. In November 2018, the US National Academies of Sciences, Engineering and Medicine organised a workshop to explore lessons from past influenza outbreaks and so develop recommendations for pandemic preparedness for 2030. The salient findings serve well to underscore the critical role of WHO for humankind.

The world’s influenza burden has only increased in the last two decades, a period in which there have also been 30 new zoonotic diseases. A warming world with increasing humidity, lost habitats and industrial livestock/poultry farming has many opportunities for pathogens to move from animals and birds to humans. Increasing global connectivity simply catalyses this process, as much as it catalyses economic growth.

WHO coordinates health research, clinical trials, drug safety, vaccine development, surveillance, virus sharing, etc. The importance of WHO’s work on immunisation across the globe, especially with HIV, can hardly be overstated. It has a rich track record of collaborating with private-sector organisations to advance research and development of health solutions and improving their access in the global south.

It discharges its duties while maintaining a dynamic equilibrium between such diverse and powerful forces as national securities, economic interests, human rights and ethics. COVID-19 has highlighted how political calculations can hamper data-sharing and mitigation efforts within and across national borders, and WHO often simply becomes a convenient political scapegoat in such situations.

International Health Regulations, a 2005 agreement between 196 countries to work together for global health security, focuses on detection, assessment and reporting of public health events, and also includes non-pharmaceutical interventions such as travel and trade restrictions. WHO coordinates and helps build capacity to implement IHR.

# Case

## Spark

### !D

#### Nuclear war can’t cause extinction – We’ve nuked ourselves 2000 times – guess what happened nothing

Eken 17 (Mattias Eken - PhD student in Modern History at the University of St Andrews whose thesis focuses on “The Enola Gay Controversy and the American Encounter with Nuclear Weapons”. <MKIM> “The understandable fear of nuclear weapons doesn’t match reality”. 3/14/17. DOA: 7/17/19. https://theconversation.com/the-understandable-fear-of-nuclear-weapons-doesnt-match-reality-73563)

Nuclear weapons are unambiguously the most destructive weapons on the planet. Pound for pound, they are the most lethal weapons ever created, capable of killing millions. Millions live in fear that these weapons will be used again, with all the potential consequences. However, the destructive power of these weapons **has been vastly exaggerated**, albeit for good reasons. Public fear of nuclear weapons being used in anger, whether by terrorists or nuclear-armed nations, has risen once again in recent years. **This is** in no small part **thanks to the current political climate** between states such as the US and Russia and the various nuclear tests conducted by North Korea. But whenever we talk about nuclear weapons, it’s easy to get carried away with doomsday scenarios and apocalyptic language. As the historian Spencer Weart once argued: “**You say ‘nuclear bomb’ and everybody immediately thinks of the end of the world.**” Yet the means necessary to produce a nuclear bomb, let alone set one off, remain incredibly complex – and while the damage that would be done if someone did in fact detonate one might be very serious indeed, **the chances that it would mean “the end of the world” are vanishingly small**. In his 2013 book Command and Control, the author Eric Schlosser tried to scare us into perpetual fear of nuclear weapons by recounting stories of near misses and accidents involving nuclear weapons. One such event, the 1980 Damascus incident, saw a Titan II intercontinental ballistic missile explode at its remote Arkansas launch facility after a maintenance crew accidentally ruptured its fuel tank. Although the warhead involved in the incident didn’t detonate, Schlosser claims that “if it had, much of Arkansas would be gone”. But that’s not quite the case. The nine-megaton thermonuclear warhead on the **Titan II** missile had a blast radius of 10km, or an area of about 315km². The state of Arkansas spreads over 133,733km², meaning the weapon **would have caused destruction across 0.2% of the state.** That would naturally have been a terrible outcome, but certainly not the catastrophe that Schlosser evokes. Claims exaggerating the effects of nuclear weapons have become commonplace, especially after the September 11 terrorist attacks in 2001. In the early War on Terror years, Richard Lugar, a former US senator and chair of the Senate Foreign Relations Committee, argued that terrorists armed with nuclear weapons pose an existential threat to the Western way of life. What he failed to explain is how. It is by no means certain that a single nuclear detonation **(or even several)** would do away with our current way of life. Indeed, we’re still here despite having nuked our own planet more than 2,000 times – a tally expressed beautifully in this video by Japanese artist Isao Hashimoto). While the 1963 Limited Test Ban Treaty forced nuclear tests underground, around 500 of all the nuclear weapons detonated were unleashed in the Earth’s atmosphere. This includes the world’s largest ever nuclear detonation, the 57-megaton bomb known as **Tsar Bomba**, detonated by the Soviet Union on October 30 1961. Tsar Bomba was more than 3,000 times more powerful than the bomb dropped on Hiroshima. That is immense destructive power – but as one physicist explained, **it’s only “one-thousandth the force of an earthquake, one-thousandth the force of a hurricane”.** The Damascus incident proved how incredibly hard it is to set off a nuclear bomb and the limited effect that would have come from just one warhead detonating. Despite this, some scientists have controversially argued that an even limited all-out nuclear war might lead to a so-called nuclear winter, since the smoke and debris created by very large bombs could block out the sun’s rays for a considerable amount of time. To inflict such ecological societal annihilation with weapons alone, we would have to detonate hundreds if not thousands of thermonuclear devices in a short time. Even in such extreme conditions, the area actually devastated by the bombs would be limited: for example, **2,000 one-megaton explosions with a destructive radius of five miles each would directly destroy less than 5% of the territory of the US**. Of course, if the effects of nuclear weapons have been greatly exaggerated, there is a very good reason: since these weapons are indeed extremely dangerous, any posturing and exaggerating which intensifies our fear of them makes us less likely to use them. But it’s important, however, to understand why people have come to fear these weapons the way we do. After all, nuclear weapons are here to stay; they can’t be “un-invented”. If we want to live with them and mitigate the very real risks they pose, we must be honest about what those risks really are. Overegging them to frighten ourselves more than we need to keeps nobody safe.

#### Rigorous climate simulations prove that hydrophilic black carbon would cause to atmospheric precipitation – results in a rainout effect that quickly reverses nuclear cooling

Reisner et al. 18 (Jon Reisner – Climate and atmospheric scientist at the Los Alamos National Laboratory. Gennaro D’Angelo – Climate scientist at the Los Alamos National Laboratory, Research scientist at the SETI institute, Associate specialist at the University of California, Santa Cruz, NASA Postdoctoral Fellow at the NASA Ames Research Center, UKAFF Fellow at the University of Exeter. Eunmo Koo - Scientist at Applied Terrestrial, Energy, and Atmospheric Modeling (ATEAM) Team, in Computational Earth Science Group (EES-16) in Earth and Environmental Sciences Division and Co-Lead of Parallel Computing Summer Research Internship (PCSRI) program at the Los Alamos National Laboratory, former Staff research associate at UC Berkeley. Wesley Even - Computational scientist in the Computational Physics and Methods Group at Los Alamos National Laboratory. Matthew Hecht – Atmospheric scientist at the Los Alamos National Laboratory. Elizabeth Hunke - Lead developer for the Los Alamos Sea Ice Model (CICE) at the Los Alamos National Laboratory responsible for development and incorporation of new parameterizations, model testing and validation, computational performance, documentation, and consultation with external model users on all aspects of sea ice modeling, including interfacing with global climate and earth system models. Darin Comeau – Climate scientist at the Los Alamos National Laboratory. Randy Bos - Project leader at the Los Alamos National Laboratory, former Weapons Effects program manager at Tech-Source. James Cooley – Computational scientist at the Los Alamos National Laboratory specializing in weapons physics, emergency response, and computational physics. <MKIM> “Climate impact of a regional nuclear weapons exchange:An improved assessment based on detailed source calculations”. 3/16/18. DOA: 7/13/19. <https://agupubs.onlinelibrary.wiley.com/doi/full/10.1002/2017JD027331>)

\*BC = Black Carbon

The no-rubble simulation produces a significantly more intense fire, with more fire spread, and consequently a significantly stronger plume with larger amounts of BC reaching into the upper atmosphere than the simulation with rubble, illustrated in Figure 5. While the no-rubble simulation **represents the worst-case scenario** involving vigorous fire activity, **only a relatively small amount of carbon makes its way into the stratosphere** during the course of the simulation. But while small compared to the surface BC mass, stratospheric BC amounts from the current simulations are significantly higher than what would be expected from burning vegetation such as trees (Heilman et al., 2014), e.g., the higher energy density of the building fuels and the initial fluence from the weapon produce an intense response within HIGRAD with initial updrafts of order 100 m/s in the lower troposphere. Or, in comparison to a mass fire, wildfires will burn only a small amount of fuel in the corresponding time period (roughly 10 minutes) that a nuclear weapon fluence can effectively ignite a large area of fuel producing an impressive atmospheric response. Figure 6 shows vertical profiles of BC multiplied by 100 (number of cities involved in the exchange) from the two simulations. The total amount of BC produced is in line with previous estimates (about 3.69 Tg from no-rubble simulation); however, the majority of BC resides **below the stratosphere** (3.46 Tg below 12 km) and can be **readily impacted by scavenging from precipitation** either via pyro-cumulonimbus produced by the fire itself (not modeled) or other synoptic weather systems. While the impact on climate of these more realistic profiles will be explored in the next section, it should be mentioned that **these estimates are** still **at the high end**, considering the inherent simplifications in the combustion model that lead to **overestimating BC production**. 3.3 Climate Results Long-term climatic effects critically depend on the initial injection height of the soot, with larger quantities reaching the upper troposphere/lower stratosphere inducing a greater cooling impact because of longer residence times (Robock et al., 2007a). Absorption of solar radiation by the BC aerosol and its subsequent radiative cooling tends to heat the surrounding air, driving an initial upward diffusion of the soot plumes, an effect that depends on the initial aerosol concentrations. **Mixing and sedimentation** tend to **reduce this process**, and low altitude emissions are also significantly impacted by precipitation if aging of the BC aerosol occurs on sufficiently rapid timescales. But once at stratospheric altitudes, aerosol dilution via coagulation is hindered by low particulate concentrations (e.g., Robock et al., 2007a) and lofting to much higher altitudes is inhibited by gravitational settling in the low-density air (Stenke et al., 2013), resulting in more stable BC concentrations over long times. Of the initial BC mass released in the atmosphere, most of which is emitted below 9 km, **70% rains out within the first month** and 78%, or about 2.9 Tg, is removed within the first two months (Figure 7, solid line), with the remainder (about 0.8 Tg, dashed line) being transported above about 12 km (200 hPa) within the first week. This outcome differs from the findings of, e.g., Stenke et al. (2013, their high BC-load cases) and Mills et al. (2014), who found that most of the BC mass (between 60 and 70%) is lifted in the stratosphere within the first couple of weeks. This can also be seen in Figure 8 (red lines) and in Figure 9, which include results from our calculation with the initial BC distribution from Mills et al. (2014). In that case, only 30% of the initial BC mass rains out in the troposphere during the first two weeks after the exchange, with the remainder rising to the stratosphere. In the study of Mills et al. (2008) this percentage is somewhat smaller, about 20%, and smaller still in the experiments of Robock et al. (2007a) in which the soot is initially emitted in the upper troposphere or higher. In Figure 7, the e-folding timescale for the removal of tropospheric soot, here interpreted as the time required for an initial drop of a factor e, is about one week. This result compares favorably with the “LT” experiment of Robock et al. (2007a), considering 5 Tg of BC released in the lower troposphere, in which 50% of the aerosols are removed within two weeks. By contrast, the initial e-folding timescale for the removal of stratospheric soot in Figure 8 is about 4.2 years (blue solid line), compared to about 8.4 years for the calculation using Mills et al. (2014) initial BC emission (red solid line). The removal timescale from our forced ensemble simulations is close to those obtained by Mills et al. (2008) in their 1 Tg experiment, by Robock et al. (2007a) in their experiment “UT 1 Tg”, and © 2018 American Geophysical Union. All rights reserved. by Stenke et al. (2013) in their experiment “Exp1”, in all of which 1 Tg of soot was emitted in the atmosphere in the aftermath of the exchange. Notably, the e-folding timescale for the decline of the BC mass in Figure 8 (blue solid line) is also close to the value of about 4 years quoted by Pausata et al. (2016) for their long-term “intermediate” scenario. In that scenario, which is also based on 5 Tg of soot initially distributed as in Mills et al. (2014), the factor-of2 shorter residence time of the aerosols is caused by particle growth via coagulation of BC with organic carbon. Figure 9 shows the BC mass-mixing ratio, horizontally averaged over the globe, as a function of atmospheric pressure (height) and time. The BC distributions used in our simulations imply that the upward transport of particles is substantially less efficient compared to the case in which 5 Tg of BC is directly injected into the upper troposphere. The semiannual cycle of lofting and sinking of the aerosols is associated with atmospheric heating and cooling during the solstice in each hemisphere (Robock et al., 2007a). During the first year, the oscillation amplitude in our forced ensemble simulations is particularly large during the summer solstice, compared to that during the winter solstice (see bottom panel of Figure 9), because of the higher soot concentrations in the Northern Hemisphere, as can be seen in Figure 11 (see also left panel of Figure 12). Comparing the top and bottom panels of Figure 9, the BC reaches the highest altitudes during the first year in both cases, but the concentrations at 0.1 hPa in the top panel can be 200 times as large. Qualitatively, the difference can be understood in terms of the air temperature increase caused by BC radiation emission, which is several tens of kelvin degrees in the simulations of Robock et al. (2007a, see their Figure 4), Mills et al. (2008, see their Figure 5), Stenke et al. (2013, see high-load cases in their Figure 4), Mills et al. (2014, see their Figure 7), and Pausata et al. (2016, see one-day emission cases in their Figure 1), due to high BC concentrations, but it amounts to only about 10 K in our forced ensemble simulations, as illustrated in Figure 10. Results similar to those presented in Figure 10 were obtained from the experiment “Exp1” performed by Stenke et al. (2013, see their Figure 4). **In that scenario as well, somewhat less that 1 Tg of BC remained in the atmosphere after the initial rainout**. As mentioned before, the BC aerosol that remains in the atmosphere, lifted to stratospheric heights by the rising soot plumes, undergoes sedimentation over a timescale of several years (Figures 8 and 9). This mass represents the effective amount of BC that can force climatic changes over multi-year timescales. In the forced ensemble simulations, it is about 0.8 Tg after the initial rainout, whereas it is about 3.4 Tg in the simulation with an initial soot distribution as in Mills et al. (2014). Our more realistic source simulation involves the worstcase assumption of no-rubble (along with other assumptions) and hence serves as an upper bound for the impact on climate. As mentioned above and further discussed below, our scenario induces perturbations on the climate system similar to those found in previous studies in which the climatic response was driven by roughly 1 Tg of soot rising to stratospheric heights following the exchange. Figure 11 illustrates the vertically integrated mass-mixing ratio of BC over the globe, at various times after the exchange for the simulation using the initial BC distribution of Mills et al. (2014, upper panels) and as an average from the forced ensemble members (lower panels). All simulations predict enhanced concentrations at high latitudes during the first year after the exchange. In the cases shown in the top panels, however, these high concentrations persist for several years (see also Figure 1 of Mills et al., 2014), whereas the forced ensemble simulations indicate that the BC concentration starts to decline after the first year. In fact, in the simulation represented in the top panels, mass-mixing ratios larger than about 1 kg of BC © 2018 American Geophysical Union. All rights reserved. per Tg of air persist for well over 10 years after the exchange, whereas they only last for 3 years in our forced simulations (compare top and middle panels of Figure 9). After the first year, values drop below 3 kg BC/Tg air, whereas it takes about 8 years to reach these values in the simulation in the top panels (see also Robock et al., 2007a). Over crop-producing, midlatitude regions in the Northern Hemisphere, the BC loading is reduced from more than 0.8 kg BC/Tg air in the simulation in the top panels to 0.2-0.4 kg BC/Tg air in our forced simulations (see middle and right panels). The more rapid clearing of the atmosphere in the forced ensemble is also signaled by the soot optical depth in the visible radiation spectrum, which drops below values of 0.03 toward the second half of the first year at mid latitudes in the Northern Hemisphere, and everywhere on the globe after about 2.5 years (without never attaining this value in the Southern Hemisphere). In contrast, the soot optical depth in the calculation shown in the top panels of Figure 11 becomes smaller than 0.03 everywhere only after about 10 years. The two cases show a similar tendency, in that the BC optical depth is typically lower between latitudes 30º S-30º N than it is at other latitudes. This behavior is associated to the persistence of stratospheric soot toward high-latitudes and the Arctic/Antarctic regions, as illustrated by the zonally-averaged, column-integrated mass-mixing ratio of the BC in Figure 12 for both the forced ensemble simulations (left panel) and the simulation with an initial 5 Tg BC emission in the upper troposphere (right panel). The spread in the globally averaged (near) surface temperature of the atmosphere, from the control (left panel) and forced (right panel) ensembles, is displayed in Figure 13. For each month, the plots show the largest variations (i.e., maximum and minimum values), within each ensemble of values obtained for that month, relative to the mean value of that month. The plot also shows yearly-averaged data (thinner lines). The spread is comparable in the control and forced ensembles, with average values calculated over the 33-years run length of 0.4-0.5 K. This spread is also similar to the internal variability of the globally averaged surface temperature quoted for the NCAR Large Ensemble Community Project (Kay et al., 2015). These results imply that surface air temperature differences, between forced and control simulations, which lie within the spread may not be distinguished from effects due to internal variability of the two simulation ensembles. Figure 14 shows the difference in the globally averaged surface temperature of the atmosphere (top panel), net solar radiation flux at surface (middle panel), and precipitation rate (bottom panel), computed as the (forced minus control) difference in ensemble mean values. The sum of standard deviations from each ensemble is shaded. Differences are qualitatively significant over the first few years, when the anomalies lie near or outside the total standard deviation. Inside the shaded region, differences may not be distinguished from those arising from the internal variability of one or both ensembles. The surface solar flux (middle panel) is the quantity that appears most affected by the BC emission, with qualitatively significant differences persisting for about 5 years. The precipitation rate (bottom panel) is instead affected only at the very beginning of the simulations. The red lines in all panels show the results from the simulation applying the initial BC distribution of Mills et al. (2014), where the period of significant impact is much longer owing to the higher altitude of the initial soot distribution that results in longer residence times of the BC aerosol in the atmosphere. When yearly averages of the same quantities are performed over the IndiaPakistan region, the differences in ensemble mean values lie within the total standard deviations of the two ensembles. The results in Figure 14 can also be compared to the outcomes of other previous studies. In their experiment “UT 1 Tg”, Robock et al. (2007a) found that, when only 1 Tg of soot © 2018 American Geophysical Union. All rights reserved. remains in the atmosphere after the initial rainout, temperature and precipitation anomalies are about 20% of those obtained from their standard 5 Tg BC emission case. Therefore, the largest differences they observed, during the first few years after the exchange, were about - 0.3 K and -0.06 mm/day, respectively, comparable to the anomalies in the top and bottom panels of Figure 14. Their standard 5 Tg emission case resulted in a solar radiation flux anomaly at surface of -12 W/m2 after the second year (see their Figure 3), between 5 and 6 time as large as the corresponding anomalies from our ensembles shown in the middle panel. In their experiment “Exp1”, Stenke et al. (2013) reported global mean surface temperature anomalies not exceeding about 0.3 K in magnitude and precipitation anomalies hovering around -0.07 mm/day during the first few years, again consistent with the results of Figure 14. In a recent study, Pausata et al. (2016) considered the effects of an admixture of BC and organic carbon aerosols, both of which would be emitted in the atmosphere in the aftermath of a nuclear exchange. In particular, they concentrated on the effects of coagulation of these aerosol species and examined their climatic impacts. The initial BC distribution was as in Mills et al. (2014), although the soot burden was released in the atmosphere over time periods of various lengths. Most relevant to our and other previous work are their one-day emission scenarios. They found that, during the first year, the largest values of the atmospheric surface temperature anomalies ranged between about -0.5 and -1.3 K, those of the sea surface temperature anomalies ranged between -0.2 and -0.55 K, and those of the precipitation anomalies varied between -0.15 and -0.2 mm/day. All these ranges are compatible with our results shown in Figure 14 as red lines and with those of Mills et al. (2014, see their Figures 3 and 6). As already mentioned in Section 2.3, the net solar flux anomalies at surface are also consistent. This overall agreement suggests that the **inclusion of organic carbon aerosols, and** ensuing **coagulation** with BC, **should not dramatically alter the climatic effects** resulting from our forced ensemble simulations. Moreover, aerosol growth would likely **shorten the residence time of the BC particulate in the atmosphere** (Pausata et al., 2016), possibly **reducing the duration of these effects.**

#### No Famines—we have food stockpiles, crop relocation from high UV areas, and indoor growing that solve food production even if they win nuclear war.

Dekenberger et al 17 (David C. Denkenberger, Assistant Professor and Research Fellow at Global Catastrophic Risk Institute, B.S. from Penn State in Engineering Science, his M.S.E. from Princeton in Mechanical and Aerospace Engineering, and his Ph.D. from the University of Colorado at Boulder; D. Dorothea Cole, Tennessee State University; Mohamed Abdelkhaliq, Tennessee State University; Michael Griswold, Tennessee State University; Allen B. Hundley, worked as a technical consultant in a number of the countries; Joshua M. Pearce, PhD, Professor at Michigan Technological University; “Feeding Everyone if the Sun is Obscured and Industry is Disabled”; International Journal of Disaster Risk Reduction; March; https://www.sciencedirect.com/science/article/pii/S2212420916305453?via%3Dihub; Accessed 10/10/19, EB)

3.1 Stored Food and Agriculture in Reduced Solar Conditions Global grain production is ∼2.7 billion tons (Gt)/yr (Tilman et al., 2002), and grains are ∼29% total of fiber and moisture (Hurburgh, 2006; United States Department of Agriculture, 2006). Therefore, this is ∼1.9 Gt/yr dry carbohydrate equivalent. Grains make up half of the calories produced (Meadows et al., 2004); thus, the total food production is ∼3.8 Gt dry/yr. The food requirement with low waste is 1.5 Gt/yr (Denkenberger and Pearce, 2014). Livestock consume 35% of the world’s grain (Earth Policy Institute, 2011). Therefore, the initial state before the catastrophe shows a plant production of 210% of requirement (not including the part that goes to livestock) and 10% of requirement animal products (see Figure 1).

#### Even if there’s no rainout, no famine – plenty of foods can survive the conditions

Bendix 20 (Aria Bendix is a Senior Reporter at Insider, covering urban and environmental science, A full-scale nuclear winter would trigger a global famine. A disaster expert put together a doomsday diet to save humanity, Jan 10, 2020, BuisnessInsider, <https://www.businessinsider.com/how-to-survive-after-nuclear-war-what-to-eat-2020-1>, 3/24/20)//ww BJ

Even if a nuclear winter destroyed trillions of trees, mushrooms could feed on that dead matter, creating a regenerative food source that could potentially feed everyone on the planet for about three years, according to Denkenberger's estimates. Since mushrooms don't rely on photosynthesis, they can survive without much light. The same goes for seaweed. "Seaweed is a really good food source in a scenario like this because it can tolerate a low light levels," Denkenberger said. "It's also very fast-growing. In a nuclear winter, the land will cool down faster than the oceans, so the oceans will remain a little bit warmer. Seaweed can handle relatively low temperatures." To feed everyone on the planet, Denkenberger estimates that the world would need around 1.6 billion tons of dry food per year. Humans could potentially grow that amount of seaweed, he said, in three to six months. But in order consume the proper nutrients to ward off disease, humans can't rely on a single food source (or two). So Denkenberger put together a chart of what a typical 2,100-calorie diet might look like in a post-doomsday scenario. nuclear winter diet David Denkenberger and Joshua M. Pearce The diet involves a mixture of meat, eggs, sugar, and mushrooms. It also includes dandelions and tea made from tree needles, which contain Vitamin C. Naturally growing bacteria would serve as a source of Vitamin E, which is important for brain function. Denkenberger said he plans to study other natural food sources that could grow near the equator, where there would still be some sunlight post-disaster (though the temperature would be low). "One of the things I've learned by moving to Alaska is that, even in areas where the summers are so cool that trees cannot grow, you can actually grow potatoes," he said. Leaves also contain stringy fiber (cellulose) that could be converted into sugar, Denkenberger added. That process is already happening at biofuel plants, which convert cellulose into sugar to make ethanol.

### Transition

#### Nuke war won’t cause extinction— BUT, it’ll spur political will for meaningful disarmament.

Daniel Deudney 18. Associate Professor of Political Science at Johns Hopkins University. 03/15/2018. “The Great Debate.” The Oxford Handbook of International Security. www.oxfordhandbooks.com, doi:10.1093/oxfordhb/9780198777854.013.22. //reem

Although nuclear war is the oldest of these technogenic threats to civilization and human survival, and although important steps to restraint, particularly at the end of the Cold War, have been achieved, the nuclear world is increasingly changing in major ways, and in almost entirely dangerous directions. The third “bombs away” phase of the great debate on the nuclear-political question is more consequentially divided than in the first two phases. Even more ominously, most of the momentum lies with the forces that are pulling states toward nuclear-use, and with the radical actors bent on inflicting catastrophic damage on the leading states in the international system, particularly the United States. In contrast, the arms control project, although intellectually vibrant, is largely in retreat on the world political stage. The arms control settlement of the Cold War is unraveling, and the world public is more divided and distracted than ever. With the recent election of President Donald Trump, the United States, which has played such a dominant role in nuclear politics since its scientists invented these fiendish engines, now has an impulsive and uninformed leader, boding ill for nuclear restraint and effective crisis management. Given current trends, it is prudent to assume that sooner or later, and probably sooner, nuclear weapons will again be the used in war. But this bad news may contain a “silver lining” of good news. Unlike a general nuclear war that might have occurred during the Cold War, such a nuclear event now would probably not mark the end of civilization (or of humanity), due to the great reductions in nuclear forces achieved at the end of the Cold War. Furthermore, politics on “the day after” could have immense potential for positive change. The survivors would not be likely to envy the dead, but would surely have a greatly renewed resolution for “never again. ” Such an event, completely unpredictable in its particulars, would unambiguously put the nuclear-political question back at the top of the world political agenda. It would unmistakeably remind leading states of their vulnerability It might also trigger more robust efforts to achieve the global regulation of nuclear capability. Like the bombings of Hiroshima and Nagasaki that did so much to catalyze the elevated concern for nuclear security in the early Cold War, and like the experience “at the brink” in the Cuban Missile Crisis of 1962, the now bubbling nuclear caldron holds the possibility of inaugurating a major period of institutional innovation and adjustment toward a fully “bombs away” future.

#### Movements will literally overthrow recalcitrant governments. Nuclear use makes the audience costs huge.

Steven R. David 18. Professor of Political Science at Johns Hopkins University. 2018. “The Nuclear Worlds of 2030.” Fletcher Forum of World Affairs, vol. 42, pp. 107–118. //reem

CATASTROPHE AND THE END OF NUCLEAR WEAPONS In the year 2025, the world very nearly came to an end. Smarting after several years of economic downturn and angry at American efforts to encircle it with NATO bases, Russia responded to a "plea" for help from co-ethnics in the Baltic states. Thousands of Russian troops, disguised as contract "volunteers" dashed across international borders allegedly to protect Russian speakers from governmental assaults. The Baltic countries invoked Article 5 of the NATO Treaty while American forces, deployed there precisely to deter this kind of aggression, clashed with Russian troops. Hundreds of Americans were killed. Washington warned Moscow to halt its invasion to no avail. The United States then prepared for a major airlift of its forces to the beleaguered countries, with Moscow threatening America with "unrestrained force" if it followed through. Washington ignored the threat and Moscow, seeking to "de-escalate by escalating," destroyed the American base of Diego Garcia in the Indian Ocean with a nuclear-armed cruise missile. The United States responded with limited nuclear strikes against Russian bases in Siberia. Thus far, the collateral damage had been kept to a minimum, but this bit of encouragement did not last. Fearing a massive American pre-emptive strike aimed at disarming its nuclear arsenal, Russia struck first against the range of US nuclear forces both in the United States and at sea. America responded with its surviving weapons, destroying much (but not all) of the remaining Russian nuclear arms. And then, both sides took a breather, but it was too late. Although cities had been largely spared, millions had died on each side. Making matters worse, predictions of nuclear winter came to pass - producing massive changes in the weather and killing millions more, especially in developing states. The world finally had enough. A dawning realization emerged that leaders of countries simply could not be trusted with weapons that could destroy humankind.3 Protests swept the globe calling for total disarmament. Mass demonstrations engulfed the United States and Russia demanding the replacement of their existing governments with ones committed to ending nuclear weapons. Voices calling for more moderate disarmament that would preserve a modest nuclear deterrent were angrily (and sometimes violently) quashed. The possession of nuclear weapons became morally repugnant and unacceptable. No longer were the intricacies of nuclear doctrine or force levels subject to debate. The only question remaining was how one could get rid of these loathsome weapons as quickly as possible. Under the auspices of the United Nations, a joint committee composed of the Security Council members, other countries known to possess nuclear arms, and several non-nuclear powers was established. Drawing on the structure and precedent of the Chemical Weapons Convention, this UN body drew up the Treaty that called for the complete disarmament of nuclear arms by 2030. The development, possession, and use of nuclear weapons was prohibited. An airtight inspection regime, enhancing the procedures already in existence through the Non-Proliferation Treaty, was established to first account for all nuclear arms and fissile material and then monitor the destruction of the nuclear weaponry. All countries were subject to the Treaty, whether they maintained nuclear facilities or not. Violations would produce a range of punishment from global economic sanctions to massive conventional attack.' 6 By 2030, all the nations of the world had agreed to the Treaty. No violations occurred. Armed conflicts persisted, but they proved to be of modest scale, erupting only within countries but not between them. Insofar as the fear of nuclear weapons helped keep the peace during the Cold War and post-Cold War eras, the horror of nuclear use now made war all but unthinkable. A feeling of relief swept the globe as the specter of nuclear holocaust vanished, tempered only by the painful regret that it took the death of millions to realize a goal that for so many had been self-evident since 1945.

#### Nuclear war causes social change and increased approval for disarmament

Martin 82. (Brian, Professor of Social Sciences at the University of Wollongong. “How the Peace¶ Movement Should be Preparing for Nuclear War,” Bulletin of Peace Proposals, Vol. 13, No. 2, 1982, pp. 149-159)//ww BJ

As well as encouraging moves towards repressive rule, the political and social upheaval resulting from nuclear war could also provide major opportunities for rapid social change in progressive directions. Several factors would operate here.¶ (a) There would be worldwide anguish and outrage at any significant use of nuclear weapons against populations. This emotion could easily turn against established institutions.¶ (b) A nuclear war involving the US, Soviet Union and Europe would weaken or destroy the bases for imperialism and neocolonialism in poor countries, and stimulate widespread revolutionary action that could not be contained by local elites left without rich country support.¶ (c) In areas directly affected by nuclear attack, the destruction of established institutions would allow the creation of new structures.¶ Historically, periods of economic or military crisis often have preceded revolutionary change, though not always with desirable results. Crises provide opportunities for groups which are organised and able to take advantage of them. In the case of nuclear war, present governments have made some arrangements to preserve their type of rule after a nuclear war. By contrast, the peace movement is almost completely unprepared to respond to a crisis engendered by nuclear war.

## COVID

#### **Current COVID-19 patent waivers will solve the pandemics advantage**

Pti 21 [6-10-2021, "India, South Africa’s patent waiver proposal in WTO achieved tremendous mileage, progression: Commerce Secretary," Hindu, https://www.thehindu.com/news/national/india-south-africas-patent-waiver-proposal-in-wto-achieved-tremendous-mileage-progression-commerce-secretary/article34778668.ece]

The proposal of India and South Africa on providing temporary patent waiver at the World Trade Organisation (WTO) to deal with the COVID-19 pandemic has achieved tremendous mileage and progression as the WTO member countries have agreed to commence text-based negotiations on it, a top government official said on June 10. The Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council of the World Trade Organization (WTO) on June 9 agreed with consensus to start text-based negotiations on a proposal submitted by India and South Africa seeking patent waivers to deal with the COVID-19 crisis. Commerce Secretary Anup Wadhawan said that the text-based negotiations is the way forward and it means that the members have broadly and in-principle accepted the objective behind the waiver proposal. “India and South Africa’s proposal has achieved tremendous mileage and tremendous progression at a very fast pace,” he told reporters. “There is a deadline that by July-end, the members are expected to come to an agreed text. So it is a very positive development,” he added. How the objective will be given effect and to what extent and for how much duration, all that would happen though text-based negotiations, the Secretary noted. In October 2020, India and South Africa had submitted the first proposal suggesting a waiver for all WTO members on the implementation of certain provisions of the TRIPS Agreement in relation to the prevention, containment or treatment of COVID-19. In May this year, a revised proposal was submitted by 62 co-sponsors, including India, South Africa, and Indonesia. The agreement on TRIPS came into effect in January 1995. It is a multilateral agreement on intellectual property (IP) rights such as copyright, industrial designs, patents and protection of undisclosed information or trade secrets. According to the revised proposal of 62 co-sponsors, the waiver should be in force for at least three years from the date of the decision on the matter. The co-sponsors have stated that the duration has to be practical for manufacturing to be feasible and viable. The revised text has also proposed waiver for health products and technologies as the prevention, treatment or containment of COVID-19 which involves a range of things and “intellectual property issues may arise with respect to the products and technologies, their materials or components, as well as their methods and means of manufacture.”

#### 3] 1AC solvency is contingent on winning that a vaccine waiver would solve COVID, but they never prove the infrastructure exists – prefer the NC evidence – it’s a key internal link to aff solvency that they just didn’t bother reading.

**No solvency and reject "empirical" claims -- vaccines require complex infrastructure to manufacture, not just patents**

**Hotez 5/10** [Peter J. Hotez, Maria Elena Bottazzi, and Prashant Yadav. "Producing a Vaccine Requires More Than a Patent," Foreign Affairs, 5-10-2021, accessed 8-8-2021, https://www.foreignaffairs.com/articles/united-states/2021-05-10/producing-vaccine-requires-more-patent] HWIC

On May 5, President Joe Biden announced that the United States would support an international bid to waive intellectual property rights to vaccines for the duration of the coronavirus pandemic, thereby ostensibly allowing other countries to ramp up production even of the sophisticated technology behind the Pfizer-BioNTech and Moderna vaccines against COVID-19. Many in the global health community and developing world welcomed the decision as a victory for greater equity in vaccine distribution, in which middle- and low-income countries are lagging far behind wealthy ones. But the jubilation may be premature. The drive for intellectual property waivers originates in part from the world’s experience fighting the last war, against HIV/AIDS. Patent pools, intellectual property waivers, and other liberalizing mechanisms were urgent in assuring equity of access to lifesaving drugs during that epidemic. But these tools are better suited to medicines and other pharmaceuticals than to vaccines. Producing vaccines—particularly those as technologically complex as the messenger RNA (mRNA) inoculations against COVID-19—requires not only patents but an entire infrastructure that cannot be transferred overnight. The sharing of patents is an important and welcome development for the long term, but it may not even be the most pressing first step. JUST OPEN THE SPIGOT At the turn of the millennium, multinational pharmaceutical companies were charging $10,000 per patient for a daily drug regimen that could keep those infected with HIV/AIDS alive. Those in low- and middle-income countries in Africa and elsewhere could access this cocktail only under limited circumstances. Then, in 2001, the Indian drug manufacturer Cipla Limited began producing versions of a triple antiretroviral drug cocktail for a mere $350. Cipla, in collaboration with Médecins Sans Frontières (Doctors Without Borders), helped usher in a new era of global access to essential medicines—one that justified relaxing or even ignoring international patents and other property rights to produce and distribute an important and lifesaving drug as a generic. Since that time, global health advocacy organizations have found increasingly sophisticated ways to work with multinationals in ensuring access to essential medicines for low- and middle-income countries. In the 2010s, the global health initiative Unitaid helped create a Medicines Patent Pool, in which pharmaceutical companies from all over the world offered antiretroviral drug licenses, thereby creating a path for developing generic versions so long as the patent holders received royalties. The mechanism supplied voluntary licenses to new producers even while protecting the legal rights of the drugs’ original manufacturers. Companies such as Gilead, for example, have supplied voluntary licenses for their antivirals directly to generic manufacturers, allowing for tiered pricing across countries. Barely any COVID-19 vaccines have been administered in the African continent or in low- or middle-income countries in Asia and Latin America. Global health professionals have understandably sought to ascertain whether a similar approach could help make the distribution of COVID-19 vaccines less lopsided. More than one billion vaccine doses have now been administered—but overwhelmingly to people living in just a few countries. More than half have been administered in the United States (250 million) and China (290 million) alone, followed by India (160 million), the United Kingdom (51 million), and Germany (32 million). In contrast, for all practical purposes, barely any COVID-19 vaccines have been [administered](https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html) in the African continent or in low- or middle-income countries in Asia and Latin America. Global health advocates have responded to this inequity by seeking to apply the lessons they learned from antiretroviral drugs and demanding patent pools or other intellectual property waivers for COVID-19 vaccines. In March 2021, Médecins Sans Frontières organized protests at the World Trade Organization (WTO) headquarters in Geneva, unfurling a banner that read, “No COVID Monopolies—Wealthy Countries Stop Blocking TRIPS Waiver,” referring to the organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights. The assumption underlying such demands is that intellectual property is a crucial barrier blocking vaccine developers, especially in low- and middle-income countries, from producing COVID-19 vaccines to scale—particularly the high-performing mRNA vaccines that Pfizer-BioNTech and Moderna currently produce. These vaccines elicit more than 90 percent protective immunity against both symptomatic illness and documented infection, including asymptomatic infection, with COVID-19. They are successfully driving the recovery of the United States, Israel, and other nations. But so far, mRNA vaccines are mostly invisible to Africa, Latin America, and low- and middle-income countries in other regions. The hope of those pushing for TRIPS waivers and patent pools is that these will unleash the technology to make the recovery global. IT TAKES A WHOLE ECOSYSTEM Intellectual property sharing may be helpful in the long term. But producing complicated biologics, especially innovative ones such as mRNA or adenovirus-vectored vaccines, is not solely a matter of patent access. Small-molecule antiviral drugs are comparatively straightforward: the multistep chemical processes through which they are synthesized are often fully detailed in published patents or scientific papers. Chemists and formulation experts can often synthesize and scale up production just from knowing the drug structure. But vaccines are different. Producing and manufacturing lipid-encased mRNA molecules, recombinant adenoviruses, or even the proteins or whole inactivated viruses used in older-generation vaccines requires a far higher level of sophistication than is needed for producing small-molecule drugs. Moreover, vaccine production must meet stringent requirements for quality control, quality assurance, and regulatory oversight. The **effective transfer of such complex technology requires a receiving ecosystem that can take years, sometimes decades, to build**. Countries seeking to ramp up vaccine production will need to train staff scientists and technicians. They will also need scientific administrators versed not only in basic research and development but also in detailed record keeping, including specific documentation practices such as batch production records. Moreover, they will need strong quality control systems and regulatory guardrails. Building such an infrastructure requires intensive training and often considerable financial investment and risk. It also takes time—by some estimates, vaccine development requires at least 11 years, and even then the probability that such efforts will result in bringing a vaccine to market is less than ten percent. Consider that the COVID-19 vaccines were themselves the outcome of decades of research and development. Few nations are prepared to take such risks. Only a handful of low- or middle-income countries currently have the capacity to produce new vaccines. Only a handful of low- or middle-income countries currently have the capacity to produce new vaccines. The most notable and largest is India, which currently makes the adenovirus-vectored vaccines developed by Janssen and by Oxford and AstraZeneca, as well as an older-technology recombinant protein vaccine and a whole inactivated virus vaccine. Manufacturers in Brazil, Cuba, and some Southeast Asian countries have experience producing childhood vaccines and may be able to develop the capacity to make COVID-19 vaccines as well. Other possibilities may develop elsewhere, including in the Middle East and Africa. But in the near term, such manufacturers will require financing, access to very large amounts of raw materials and supplies (possibly including relaxation of export controls), and some technical expertise in manufacturing and quality control if they are to produce the existing vaccines against COVID-19. Vaccinating India alone will require almost two billion doses, and more than 12 billion doses will be required to vaccinate the world. The emergence of new variants and the need for booster doses may increase demand even further. Whether mRNA vaccine technology can be scaled to produce billions of doses in 2021, or even by early 2022, remains entirely unknown, but the goal is worth pursuing. To this end, some kind of patent relaxation may be necessary, but far from sufficient. Would-be producers will need technical know-how, regulatory controls, and components that are currently in very short supply, such as nucleotides and lipids.

#### Tech transfer is key and not included under IP

Smith 05/05

(Laura Smith-Spark; Newsdesk Editor, CNN Digital; (05-05-21) Rich nations urged to share vaccine knowledge while WTO debates waiving patents; CNN; <https://www.cnn.com/2021/05/05/world/covid-19-vaccine-patents-wto-intl/index.html>; CKD)

Thomas Bollyky, director of the Global Health Program at the Council on Foreign Relations, told CNN on Friday that what's really needed to scale up global manufacturing of vaccines is technology transfer. "It's not just a matter of intellectual property. It's also the transfer of know-how," he said. "I don't think there's clear evidence that a waiver of an intellectual property is going to be the best way for that technology transfer to occur." Waiving patents will not work in the same way for vaccines as it has for drugs, Bollyky said. For HIV drugs, for example, manufacturers were more or less able to reverse engineer them without much help from the original developer. "It's very different for vaccines, where it's really a biological process as much as a product. It's hard to scale up manufacturing in this process for the original company, let alone another manufacturer trying to figure this out without assistance," he said. "It requires a lot of knowledge that's not part of the IP." The deal between AstraZeneca and the Serum Institute of India is a successful example of such technology transfer, Bollyky said, where the licensing of IP happened voluntarily. "The question is what can we do to facilitate more deals like the one between AstraZeneca and the Serum Institute of India to have this transfer," he said. Michael Head, senior research fellow in global health at the University of Southampton, in England, told CNN that increasing regional manufacturing capacity, particularly in the global south, was key -- and should be a focus between pandemics. "Sharing intellectual property during the pandemic is something that should happen but that doesn't resolve the issues," he said. "Manufacturing vaccines is hard. It's hard to rapidly set up a new site with all the equipment, infrastructure, all the vaccine ingredients, with suitable staff to produce a large number of high quality vaccine products." Philanthropist Bill Gates, a major supporter of [global Covid-19 vaccine equity](https://www.cnn.com/2021/02/05/world/covax-explainer-intl/index.html) through the Bill & Melinda Gates Foundation, also [told Sky News](https://news.sky.com/story/covid-19-bill-gates-hopeful-world-completely-back-to-normal-by-end-of-2022-and-vaccine-sharing-to-ramp-up-12285840) last month that he did not believe overriding IP rules was the answer. "There's only so many vaccine factories in the world and people are very serious about the safety of vaccines," he said. "The thing that's holding things back in this case is not intellectual property. There's not, like, some idle vaccine factory with regulatory approval that makes magically safe vaccines. You've got to do the trials on these things and every manufacturing process has to be looked at in a very careful way."

#### The squo is goldilocks--COVAX and licensing agreements ensure vaccine access now, but patent waiver causes unsafe vaccines and decks innovation.

Crosby et al. 21 (Daniel Crosby [Lawyer specializing in international trade/law], Evan Diamond [Lawyer specializing in pharmaceutical and biotechnology patent litigation], Isabel Fernandez de la Cuesta [Lawyer specializing in international treaty arbitration], Jamieson Greer [Lawyer specializing in international trade], Jeffrey Telep [Lawyer specializing in international trade litigation], Brian White [Lawyer specializing in international arbitration], Group of Nearly 60 WTO Members Seek Unprecedented Waiver from WTO Intellectual Property Protection for COVID-related Medical Products, JD Supra, 3/5/2021, <https://www.jdsupra.com/legalnews/group-of-nearly-60-wto-members-seek-2523821/>) hwof

Efforts to develop, produce, and equitably distribute medical products. WTO Members recognize that unprecedented demand for medical products used in the fight against COVID-19 has far outstripped supply of required supplies. Several WTO Members have pointed out that intellectual property protections have not limited production of vaccines and other medical products. Rather, these Members have argued that intellectual property protection has incentivized the research, development and production of the necessary vaccines, treatments and products. Moreover, the international community is coordinating and funding equitable COVID-19 vaccine distribution globally through COVAX, which is organized by Gavi, the Vaccine Alliance, the World Health Organization and the Coalition for Epidemic Preparedness Innovations. Despite these facts, less developed countries continue to push for a waiver of all intellectual property protection for medical products related to the pandemic. Waiver risks uncontrolled use of patented technologies, without improving vaccine access. Pharmaceutical companies can provide, and have provided, licenses to distribute or scale-up production of COVID-19 vaccines and therapies at reduced cost. Such license agreements allow for expanded access in low- and middle-income countries, while also setting reasonable parameters so that patents and other IP rights are used to address the specific medical needs of the COVID-19

pandemic at hand, and not for other purposes. License agreements also allow for orderly technology transfer, including of unpatented “trade secret” information and other critical “know-how,” that may be essential to efficiently producing and scaling-up safe and effective versions of technologically complex vaccines and biologic drug products. Under the present TRIPS waiver proposal, however, member countries could try to exploit an extraordinarily broad scope of IP and copy patented technologies so long as they are “in relation to prevention, containment or treatment of COVID-19.” For example, under an expansive reading of the proposed waiver language, a member country could try to produce patented pharmaceutical compounds that have other indicated uses predating COVID-19, if such compounds had later been studied or experimentally used for potential symptomatic relief or antiviral activity in COVID-19 patients. The same risks may be faced by manufacturers of patented materials or devices that have multiple uses predating COVID-19, but also may be used as “personal protective equipment” or components thereof, or in other measures arguably relating to COVID-19 “prevention” or “containment.” At the same time, it is unclear how the proposed TRIPS waiver could provide the technology transfer and know-how critical for making the complex molecules and formulations constituting the various COVID-19 vaccines. Vaccine manufacture undertaken by an unauthorized party without the proper processes and controls could result in a different product that is potentially ineffective or results in unwanted health consequences. And even if an unauthorized manufacturer could overcome those substantial hurdles to reverse-engineer and scale up a safe and effective vaccine copy, it would likely take substantial time and a series of failures to do so. Notably, several of the original COVID-19 vaccine developers have recently faced low product yield and other manufacturing challenges during pre-commercial scale-up efforts and the initial months of commercial production.

#### A vaccine waiver greenlights counterfeit medicine – independently turns Case.

Conrad 5-18 John Conrad 5-18-2021 "Waiving intellectual property rights is not in the best interests of patients" <https://archive.is/vsNXv#selection-5353.0-5364.0> (president and CEO of the Illinois Biotechnology Innovation Organization in Chicago.)//Elmer

The Biden's administration's support for India and South Africa's proposal before the World Trade Organization to temporarily waive anti-COVID vaccine patents to boost its supply will fuel the **development of counterfeit vaccines and weaken the already strained global supply chain**. The proposal will not increase the effective number of COVID-19 vaccines in India and other countries. The manufacturing standards to produce COVID-19 vaccines are **exceptionally complicated**; it is unlike any other manufacturing process. To ensure patient safety and efficacy, only manufacturers with the **proper facilities and training should produce the vaccine, and they are**. Allowing a temporary waiver that permits compulsory licensing to allow a manufacturer to export counterfeit vaccines will **cause confusion and endanger public health**. For example, between 60,000 and 80,000 children in Niger with fatal falciparum malaria were treated with a counterfeit vaccine containing incorrect active pharmaceutical ingredients, resulting in more than **100 fatal infections.** Beyond the patients impacted, counterfeit drugs erode public confidence in health care systems and the pharmaceutical industry. Vaccine hesitancy is a rampant threat that feeds off of the distribution of misinformation. Allowing the production of vaccines from improper manufacturing facilities further opens the door for antivaccine hacks to stoke the fear fueling **vaccine hesitance**.

#### The Plan can’t solve COVID - Lack of key supplies – ow on recency

Tepper 21 James Tepper, 4/10 [James Tepper, (James M. Tepper is an American neuroscientist currently a Board of Governors Professor of Molecular and Behavioral Neuroscience and Distinguished Professor at Rutgers University and an Elected Fellow of the American Association for the Advancement of Science.)]. "Global Covid vaccine rollout threatened by shortage of vital components." Guardian, 4-10-2021, Accessed 8-8-2021. https://www.theguardian.com/world/2021/apr/10/global-covid-vaccine-rollout-threatened-by-shortage-of-vital-components // duongie

Vaccine-makers around the world face shortages of vital components including large plastic growbags, according to the head of the firm that is manufacturing a quarter of the UK’s jab supply. Stan Erck, the chief executive of Novavax – which makes the second vaccine to be grown and bottled entirely in Britain – told the Observer that the shortage of 2,000-litre bags in which the vaccine cells were grown was a significant hurdle for global supply. His warning came as bag manufacturers revealed that some pharmaceutical firms were waiting up to 12 months for the sterile single-use disposable plastic containers, which are used to make medicines of all kinds, including the Pfizer, Moderna and Novavax Covid-19 vaccines. But Erck and his British partners said they were confident they had enough suppliers to avoid disruption to the supply of Novavax. The vaccine is waiting for approval from the Medicines and Healthcare products Regulatory Agency (MHRA) but the first of 60 million doses ordered by the government are already in production in Teesside. The Fujifilm Diosynth Biotechnologies factory began growing the first cells for the Novavax vaccine in Billingham, County Durham this month and in a few weeks they will fill the bioreactor bag, ready to be transported to GlaxoSmithKline’s plant at Barnard Castle to be put into vials for distribution. “The first hurdle is showing it works and we don’t have that hurdle any more,” Erck said. But he added there were others still to overcome. “There’s the media that the cells have to grow in,” Erck said. “You grow them in these 2,000-litre bags, which are in short supply. Then you pour it out and you have to filter it, and the filters are in short supply. The little things count.” Novavax almost ran out of bags at one of its 20 factories earlier this year, but there had been no delays for the UK operation, according to Martin Meeson, global chief executive of Fujifilm Diosynth. “We started working on our part of the supply chain in summer last year,” he said. “We had to accelerate some of the investment here, but the commitment we made last summer to start manufacturing in February has been fulfilled.” Production of coronavirus vaccines is being ramped up. Production of coronavirus vaccines is being ramped up. Photograph: Christophe Archambault/AP Both Meeson and Erck said the UK’s vaccine taskforce had been helpful in sorting out supply issues so far, but other countries and other medical supplies might be affected. ABEC makes bioreactor bags at two plants in the US and two in Fermoy and Kells in Ireland, and delivered six 4,000-litre bags to the Serum Institute in India last year for its Covid vaccines. Brady Cole, vice-president of equipment solutions at ABEC, said: “We are hearing from our customer base of lead times that are pushing out to nine, 10, even 12 months to get bioreactor bags. We typically run out at 16 weeks to get a custom bioreactor bag out to a customer.” He said ABEC was still managing to fulfil orders at roughly that rate. “The bag manufacturing capacity can’t meet demand right now,” he added. “And on the component side, the tubes and the instruments and so forth that also go into the bag assembly – those lead times are also starting to get stretched as well. But the biggest problem we see is it really is just the ability to get bags in a reasonable amount of time.” ABEC expanded its factories last year and has now started making 6,000-litre bags, which are roughly the size of a minibus. Other firms including MilliporeSigma, part of German company Merck, have also been expanding their manufacturing facilities. American firm Thermo Fisher Scientific expects it will finish doubling its capacity this year. The US government has also blocked exports of bags, filters and other components so it can supply more Pfizer vaccines for Americans. Adar Poonawalla, the chief executive of the Serum Institute of India, said the restrictions were likely to cause serious bottlenecks. Novavax is hoping to avoid delays and “vaccine nationalism” by operating on four continents, with 20 facilities in nine countries. “One year ago, we had exactly zero manufacturing capacity,” Erck said. “We’re self-sufficient. The two main things we need to do are done in the UK. And in the EU we have plants in Spain and the Czech Republic and fill-and-finish in Germany and the Netherlands.” There was no need for vaccines to cross borders to fulfil contracts, he said. The Oxford/AstraZeneca vaccine was hit by a delay to a delivery of 5 million doses from India and a problem with a batch made in Britain, and the company has been dragged into a lengthy row between the UK and the EU over vaccine exports.